Verona Pharma Investor Relations Material
Latest events
Q1 2025
Verona Pharma
Q2 2025
6 Aug, 2025
Investor Presentation
1 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Verona Pharma plc
Access all reports
Verona Pharma plc is a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of respiratory diseases. Its main product, ensifentrine, is designed to alleviate symptoms and improve health outcomes in conditions such as chronic obstructive pulmonary disease (COPD). The company is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Key slides for Verona Pharma plc
Investor Presentation
Verona Pharma plc
Investor Presentation
Verona Pharma plc
Latest articles
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
Ticker symbol
VRNA
Country
🇺🇸 United States